{
    "ABCG2": {
        "expression": [
            {
                "Organ": "Brain",
                "Source": "Nishimura",
                "Relative Expression": 0.0224
            },
            {
                "Organ": "Kidney*",
                "Source": "Nishimura",
                "Relative Expression": 0.00463
            },
            {
                "Organ": "Liver*",
                "Source": "Nishimura",
                "Relative Expression": 0.0139
            },
            {
                "Organ": "Placenta*",
                "Source": "Nishimura",
                "Relative Expression": 0.0954
            },
            {
                "Organ": "Small Intestine*",
                "Source": "Nishimura",
                "Relative Expression": 0.0492
            },
            {
                "Organ": "Liver*",
                "Source": "Mean across all PMT Samples",
                "Relative Expression": 1.555
            },
            {
                "Organ": "Kidney*",
                "Source": "Mean across all PMT Samples",
                "Relative Expression": 0.739
            }
        ],
        "inhibitors": [
            {
                "Inhibitor": "17beta-estradiol",
                "IC50 (μM)": 4.8,
                "Ki (μM)": null,
                "Substrate used": null,
                "Cell System": "Steroid Sensitivity of K562-BCRP",
                "Reference": "Imai, 2002"
            },
            {
                "Inhibitor": "17beta-estradiol-3-sulfate",
                "IC50 (μM)": 14.0,
                "Ki (μM)": null,
                "Substrate used": "Estrone 3-sulfate",
                "Cell System": "BCRP-expressing vesicles from mouse lymphoma (P388) cells",
                "Reference": "Suzuki, 2003"
            },
            {
                "Inhibitor": "Abacavir",
                "IC50 (μM)": 385.0,
                "Ki (μM)": null,
                "Substrate used": "Pheophorbide A",
                "Cell System": "MDCK II-BCRP",
                "Reference": "Weiss, 2007"
            },
            {
                "Inhibitor": "Amprenavir",
                "IC50 (μM)": 181.0,
                "Ki (μM)": null,
                "Substrate used": "Pheophorbide A",
                "Cell System": "MDCK II-BCRP",
                "Reference": "Weiss, 2007"
            },
            {
                "Inhibitor": "Atazanavir",
                "IC50 (μM)": 69.1,
                "Ki (μM)": null,
                "Substrate used": "Pheophorbide A",
                "Cell System": "MDCK II-BCRP",
                "Reference": "Weiss, 2007"
            },
            {
                "Inhibitor": "Atorvastatin",
                "IC50 (μM)": null,
                "Ki (μM)": 14.3,
                "Substrate used": "Estrone 3-sulfate",
                "Cell System": "BCRP-expressing HEK293 vesicles",
                "Reference": "Hirano, 2005"
            },
            {
                "Inhibitor": "Cerivastatin",
                "IC50 (μM)": null,
                "Ki (μM)": 18.1,
                "Substrate used": "Estrone 3-sulfate",
                "Cell System": "BCRP-expressing HEK293 vesicles",
                "Reference": "Hirano, 2005"
            },
            {
                "Inhibitor": "Daunomycin",
                "IC50 (μM)": 59.0,
                "Ki (μM)": null,
                "Substrate used": "Estrone 3-sulfate",
                "Cell System": "BCRP-expressing vesicles from mouse lymphoma (P388) cells",
                "Reference": "Suzuki, 2003"
            },
            {
                "Inhibitor": "Dehydroepiandrosterone sulfate",
                "IC50 (μM)": 55.0,
                "Ki (μM)": null,
                "Substrate used": "Estrone 3-sulfate",
                "Cell System": "BCRP-expressing vesicles from mouse lymphoma (P388) cells",
                "Reference": "Suzuki, 2003"
            },
            {
                "Inhibitor": "Delavirdine",
                "IC50 (μM)": 18.7,
                "Ki (μM)": null,
                "Substrate used": "Pheophorbide A",
                "Cell System": "MDCK II-BCRP",
                "Reference": "Weiss, 2007"
            },
            {
                "Inhibitor": "Efavirenz",
                "IC50 (μM)": 20.6,
                "Ki (μM)": null,
                "Substrate used": "Pheophorbide A",
                "Cell System": "MDCK II-BCRP",
                "Reference": "Weiss, 2007"
            },
            {
                "Inhibitor": "Elacridar (GF120918)",
                "IC50 (μM)": 0.31,
                "Ki (μM)": null,
                "Substrate used": "Mitoxantrone",
                "Cell System": "HEK293-BCRP",
                "Reference": "Ahmed-Belkacem, 2005"
            },
            {
                "Inhibitor": "Erlotinib",
                "IC50 (μM)": 0.13,
                "Ki (μM)": 0.15,
                "Substrate used": "Estrone 3-sulfate",
                "Cell System": "BCRP-expressing K562 vesicles",
                "Reference": "Noguchi, 2009"
            },
            {
                "Inhibitor": "Fluvastatin",
                "IC50 (μM)": null,
                "Ki (μM)": 5.43,
                "Substrate used": "Estrone 3-sulfate",
                "Cell System": "BCRP-expressing HEK293 vesicles",
                "Reference": "Hirano, 2005"
            },
            {
                "Inhibitor": "Fumitremorgin C",
                "IC50 (μM)": 0.25,
                "Ki (μM)": 0.55,
                "Substrate used": "Estrone 3-sulfate",
                "Cell System": "BCRP-expressing K562 vesicles",
                "Reference": "Noguchi, 2009"
            },
            {
                "Inhibitor": "Fumitremorgin C",
                "IC50 (μM)": 0.47,
                "Ki (μM)": null,
                "Substrate used": "Pheophorbide A",
                "Cell System": "MDCK II-BCRP",
                "Reference": "Weiss, 2007"
            },
            {
                "Inhibitor": "Ko143",
                "IC50 (μM)": 0.01,
                "Ki (μM)": null,
                "Substrate used": "Pheophorbide A",
                "Cell System": "MDCK II-BCRP",
                "Reference": "Weiss, 2007"
            },
            {
                "Inhibitor": "Lopinavir",
                "IC50 (μM)": 7.66,
                "Ki (μM)": null,
                "Substrate used": "Pheophorbide A",
                "Cell System": "MDCK II-BCRP",
                "Reference": "Weiss, 2007"
            },
            {
                "Inhibitor": "Nelfinavir",
                "IC50 (μM)": 13.5,
                "Ki (μM)": null,
                "Substrate used": "Pheophorbide A",
                "Cell System": "MDCK II-BCRP",
                "Reference": "Weiss, 2007"
            },
            {
                "Inhibitor": "Nilotinib",
                "IC50 (μM)": null,
                "Ki (μM)": 0.69,
                "Substrate used": "Methotrexate",
                "Cell System": "BCRP-expressing HEK293 vesicles",
                "Reference": "Tiwari, 2009"
            },
            {
                "Inhibitor": "Pitavastatin",
                "IC50 (μM)": null,
                "Ki (μM)": 2.92,
                "Substrate used": "Estrone 3-sulfate",
                "Cell System": "BCRP-expressing HEK293 vesicles",
                "Reference": "Hirano, 2005"
            },
            {
                "Inhibitor": "Rosuvastatin",
                "IC50 (μM)": null,
                "Ki (μM)": 15.4,
                "Substrate used": "Estrone 3-sulfate",
                "Cell System": "BCRP-expressing HEK293 vesicles",
                "Reference": "Hirano, 2005"
            },
            {
                "Inhibitor": "Saquinavir",
                "IC50 (μM)": 27.4,
                "Ki (μM)": null,
                "Substrate used": "Pheophorbide A",
                "Cell System": "MDCK II-BCRP",
                "Reference": "Weiss, 2007"
            },
            {
                "Inhibitor": "Simvastatin",
                "IC50 (μM)": null,
                "Ki (μM)": 18.0,
                "Substrate used": "Estrone 3-sulfate",
                "Cell System": "BCRP-expressing HEK293 vesicles",
                "Reference": "Hirano, 2005"
            },
            {
                "Inhibitor": "SN-38",
                "IC50 (μM)": 1.6,
                "Ki (μM)": null,
                "Substrate used": "Estrone 3-sulfate",
                "Cell System": "BCRP-expressing vesicles from mouse lymphoma (P388) cells",
                "Reference": "Suzuki, 2003"
            },
            {
                "Inhibitor": "Sulfasalazine",
                "IC50 (μM)": 0.73,
                "Ki (μM)": null,
                "Substrate used": "Estrone 3-sulfate",
                "Cell System": "BCRP-expressing oocytes",
                "Reference": "Elsby, 2011"
            }
        ],
        "substrates": [
            {
                "Substrate": "4-methylumbelliferone sulfate",
                "Km (μM)": "12.9",
                "Cell System": "BCRP-expressing vesicles from mouse lymphoma (P388) cells",
                "Reference": "Suzuki, 2003"
            },
            {
                "Substrate": "Daunorubicin",
                "Km (μM)": "2.5",
                "Cell System": "ATP hydrolysis assay of BCRP-expressing Sf9 vesicles",
                "Reference": "Ozvegy, 2001"
            },
            {
                "Substrate": "Doxorubicin",
                "Km (μM)": "5",
                "Cell System": "ATP hydrolysis assay of BCRP-expressing Sf9 vesicles",
                "Reference": "Ozvegy, 2001"
            },
            {
                "Substrate": "Estradiol-17beta-glucuronide",
                "Km (μM)": "44.2",
                "Cell System": "BCRP-expressing HEK293 vesicles",
                "Reference": "Chen, 2003"
            },
            {
                "Substrate": "Estrone 3-sulfate",
                "Km (μM)": "6.8",
                "Cell System": "BCRP-expressing K562 vesicles",
                "Reference": "Imai, 2003"
            },
            {
                "Substrate": "Estrone 3-sulfate",
                "Km (μM)": "16.6",
                "Cell System": "BCRP-expressing vesicles from mouse lymphoma (P388) cells",
                "Reference": "Suzuki, 2003"
            },
            {
                "Substrate": "Hematoporphyrin",
                "Km (μM)": "17.8",
                "Cell System": "BCRP-expressing Sf9 vesicles",
                "Reference": "Tamura, 2006"
            },
            {
                "Substrate": "Imatinib",
                "Km (μM)": "ND",
                "Cell System": "Intracellular accumulation in BCRP-expressing HEK293 cells inhbited with Ko-143",
                "Reference": "Burger, 2004"
            },
            {
                "Substrate": "Methotrexate",
                "Km (μM)": "681",
                "Cell System": "BCRP-expressing MCF7\\/MX vesicles",
                "Reference": "Volk, 2003"
            },
            {
                "Substrate": "Methotrexate",
                "Km (μM)": "1340",
                "Cell System": "BCRP-expressing HEK293 vesicles",
                "Reference": "Chen, 2003"
            },
            {
                "Substrate": "Methotrexate",
                "Km (μM)": "1410",
                "Cell System": "BCRP-expressing HEK293 vesicles",
                "Reference": "Tiwari, 2009"
            },
            {
                "Substrate": "Mitoxantrone",
                "Km (μM)": "7",
                "Cell System": "ATP hydrolysis assay of BCRP-expressing Sf9 vesicles",
                "Reference": "Ozvegy, 2001"
            },
            {
                "Substrate": "Pitavastatin*",
                "Km (μM)": "5.73",
                "Cell System": "BCRP-expressing HEK293 vesicles",
                "Reference": "Hirano, 2005"
            },
            {
                "Substrate": "Rosuvastatin*",
                "Km (μM)": "2.02",
                "Cell System": "BCRP-expressing HEK293 vesicles",
                "Reference": "Kitamura, 2008"
            },
            {
                "Substrate": "Rosuvastatin*",
                "Km (μM)": "10.1",
                "Cell System": "MDCK II-BCRP",
                "Reference": "Deng, 2008"
            },
            {
                "Substrate": "SN-38",
                "Km (μM)": "4.0",
                "Cell System": "BCRP-expressing PC-6\\/SN2-5H vesicles",
                "Reference": "Nakatomi, 2001"
            },
            {
                "Substrate": "SN-38 glucuronide",
                "Km (μM)": "26",
                "Cell System": "BCRP-expressing PC-6\\/SN2-5H vesicles",
                "Reference": "Nakatomi, 2001"
            },
            {
                "Substrate": "Sulfasalazine",
                "Km (μM)": "0.7",
                "Cell System": "BCRP-expressing Sf9 vesicles",
                "Reference": "Jani, 2009"
            },
            {
                "Substrate": "Topotecan",
                "Km (μM)": "213",
                "Cell System": "MDCK II-BCRP",
                "Reference": "Li, 2008"
            }
        ],
        "ddi": [
            {
                "DDI": "1",
                "Implicated Transporter": "ABCG2/OATPs",
                "Interacting Drug": "Atazanavir  / Ritonavir",
                "Affected Drug": "Rosuvastatin",
                "AUC": "3.1",
                "Cmax": "7.0",
                "CLR": "ND",
                "CL/F": "ND",
                "t1/2": "ND",
                "Effect on PD": "ND",
                "Reference": "Busti, 2008",
                "More Details": "DDI 1"
            },
            {
                "DDI": "2",
                "Implicated Transporter": "ABCG2/OATPs",
                "Interacting Drug": "Cyclosporine",
                "Affected Drug": "Pitavastatin",
                "AUC": "4.6",
                "Cmax": "6.6",
                "CLR": "ND",
                "CL/F": "ND",
                "t1/2": "ND",
                "Effect on PD": "ND",
                "Reference": "Livalo Drug Label",
                "More Details": "DDI 2"
            },
            {
                "DDI": "3",
                "Implicated Transporter": "ABCG2/OATPs",
                "Interacting Drug": "Cyclosporine",
                "Affected Drug": "Rosuvastatin",
                "AUC": "5.0",
                "Cmax": "10.6",
                "CLR": "ND",
                "CL/F": "ND",
                "t1/2": "ND",
                "Effect on PD": "ND",
                "Reference": "Simonson, 2004",
                "More Details": "DDI 3"
            },
            {
                "DDI": "4",
                "Implicated Transporter": "ABCG2/OATPs",
                "Interacting Drug": "Cyclosporine",
                "Affected Drug": "Rosuvastatin",
                "AUC": "6.4",
                "Cmax": "18.2",
                "CLR": "ND",
                "CL/F": "ND",
                "t1/2": "ND",
                "Effect on PD": "ND",
                "Reference": "Simonson, 2004",
                "More Details": "DDI 4"
            },
            {
                "DDI": "5",
                "Implicated Transporter": "ABCB1/ABCG2",
                "Interacting Drug": "Elacridar (GF120918)",
                "Affected Drug": "Topotecan",
                "AUC": "2.4",
                "Cmax": "2.8",
                "CLR": "ND",
                "CL/F": "ND",
                "t1/2": "NS",
                "Effect on PD": "ND",
                "Reference": "Kruijtzer, 2002",
                "More Details": "DDI 5"
            }
        ]
    }
}